Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.14 million versus the consensus estimate of $841.78 thousand.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.